Jul 15, 2009
By: Ophthalmology Times Staff Reports
Ophthalmology Times E-News
The company recently reviewed interim efficacy and safety data from more than 200 patients in a large, controlled phase II trial. The findings confirmed previous pilot clinical results that anecortave acetate applied through a single anterior juxtascleral injection measurably reduced IOP for an extended period of time, according to a prepared statement.
Based on detailed analysis of the data, however, and after gaining input from a panel of expert clinical advisers, the company said it determined that the amount of IOP reduction and the response rate provided by even the highest dose were not sufficient to support the novel approach as a viable way to address the problem of patient adherence with eye drop therapy.
Monday, August 17, 2009
Simultaneous bilateral cataract surgery a safe procedure if careful anti-infection procedures followed,
Ophthalmology Times
Although many ophthalmic surgeons avoid performing simultaneous bilateral cataract surgery because of the perceived risk of bilateral simultaneous endophthalmitis, the risk of the complication is actually miniscule when proper infection control and anti-cross-contamination procedures are followed. As refractive lens procedures are increasingly performed on younger patients, it is likely that the simultaneous bilateral procedure will become more common.more
Although many ophthalmic surgeons avoid performing simultaneous bilateral cataract surgery because of the perceived risk of bilateral simultaneous endophthalmitis, the risk of the complication is actually miniscule when proper infection control and anti-cross-contamination procedures are followed. As refractive lens procedures are increasingly performed on younger patients, it is likely that the simultaneous bilateral procedure will become more common.more
Subscribe to:
Posts (Atom)
